Literature DB >> 25406838

Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.

Sushmita D Lahiri1, Stefano Mangani, Haris Jahić, Manuela Benvenuti, Thomas F Durand-Reville, Filomena De Luca, David E Ehmann, Gian Maria Rossolini, Richard A Alm, Jean-Denis Docquier.   

Abstract

The Class D (or OXA-type) β-lactamases have expanded to be the most diverse group of serine β-lactamases with a highly heterogeneous β-lactam hydrolysis profile and are typically resistant to marketed β-lactamase inhibitors. Class D enzymes are increasingly found in multidrug resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, and various species of the Enterobacteriaceae and are posing a serious threat to the clinical utility of β-lactams including the carbapenems, which are typically reserved as the drugs of last resort. Avibactam, a novel non-β-lactam β-lactamase inhibitor, not only inhibits all class A and class C β-lactamases but also has the promise of inhibition of certain OXA enzymes, thus extending the antibacterial activity of the β-lactam used in combination to the organisms that produce these enzymes. X-ray structures of OXA-24 and OXA-48 in complex with avibactam revealed the binding mode of this inhibitor in this diverse class of enzymes and provides a rationale for selective inhibition of OXA-48 members. Additionally, various subunits of the OXA-48 structure in the asymmetric unit provide snapshots of different states of the inhibited enzyme. Overall, these data provide the first structural evidence of the exceptionally slow reversibility observed with avibactam in class D β-lactamases. Mechanisms for acylation and deacylation of avibactam by class D enzymes are proposed, and the likely extent of inhibition of class D β-lactamases by avibactam is discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25406838     DOI: 10.1021/cb500703p

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  33 in total

1.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

2.  Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens.

Authors:  Vlatko Stojanoski; Dar-Chone Chow; Bartlomiej Fryszczyn; Liya Hu; Patrice Nordmann; Laurent Poirel; Banumathi Sankaran; B V Venkataram Prasad; Timothy Palzkill
Journal:  Biochemistry       Date:  2015-05-14       Impact factor: 3.162

3.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

Review 4.  Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).

Authors:  Dana R Bowers; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

5.  Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.

Authors:  Juan Carlos Vázquez-Ucha; María Maneiro; Marta Martínez-Guitián; John Buynak; Christopher R Bethel; Robert A Bonomo; Germán Bou; Margarita Poza; Concepción González-Bello; Alejandro Beceiro
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase.

Authors:  Melina Ruggiero; Krisztina M Papp-Wallace; Magdalena A Taracila; Maria F Mojica; Christopher R Bethel; Susan D Rudin; Elise T Zeiser; Gabriel Gutkind; Robert A Bonomo; Pablo Power
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

8.  Phenotypic Detection and Differentiation of Carbapenemase Classes Including OXA-48-Like Enzymes in Enterobacterales and Pseudomonas aeruginosa by a Highly Specialized Micronaut-S Microdilution Assay.

Authors:  Niels Pfennigwerth; Sören G Gatermann; Barbara Körber-Irrgang; Robert Hönings
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

Review 9.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

Review 10.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.